How to Treat Atopic Eczema: The Full Treatment Ladder

How to Treat Atopic Eczema: The Full Treatment Ladder
By Lisa Jensen, Senior Clinical Research Associate •

Most people treat atopic eczema with whatever cream sits closest in the bathroom drawer. The class of medicine matters far more than the brand on the tube. Atopic dermatitis affects roughly one in ten adults and up to one in five children[1], and many of them never reach steady control. The reason is rarely willpower. It is usually the wrong class of medicine sitting on the wrong patch of skin.

You know the cycle. A cream calms the redness for two weeks, so you stop using it. Then the itch wakes you at 2 a.m. behind the knees, and you start over with something new. That loop is not your fault. Atopic eczema is a barrier disease and an immune disease at the same time. It needs both problems treated together[2].

This guide maps the medicine, not the marketing. You will see the full treatment ladder from moisturizer to biologic, learn how the four prescription topical classes differ, and work out which one fits your body site and your age. Finally, you will learn how to keep flares from coming back. For the wider picture across every eczema type, start with our full range of eczema treatment options.

Guidance has shifted recently, because a 2024 review of systemic therapy reshaped what dermatologists reach for first[12], and it moved several non-steroid topical options up the list as well.

Key Takeaways

  • Moisturizing twice daily cuts flare frequency and reduces how much steroid you need.
  • Four prescription topical classes exist: steroids, calcineurin inhibitors, PDE4 creams, and JAK creams.
  • Thin skin on the face, eyelids, and folds needs low-potency or non-steroid options.
  • Systemic drugs are added on top of topical care, never instead of it.
  • Twice-weekly proactive treatment of old hot spots lengthens the time between flares.

Table of Contents

How to Treat Atopic Eczema: The Stepped Approach

To treat atopic eczema, repair the barrier with a moisturizer twice a day at every severity, calm inflammation with a topical anti-inflammatory matched to your severity and body site, and step up to light therapy or systemic medicine only when well-used topicals fail. Treatment intensity climbs with severity, but the moisturizer never comes off the plan[4].

That last point is not filler. In a Cochrane review, regular use of emollients (the plain moisturizers that seal water into skin) lowered how often flares happen and reduced the amount of topical steroid people needed, though the pooled trials behind those two findings were small[3].

Atopic eczema differs from other eczema types because two problems run at the same time. The first is a leaky skin barrier, a bit like a brick wall with crumbling mortar that lets water escape and irritants slip in. The second is an overactive branch of the immune system called the type 2 response, which floods the skin with chemical messengers known as cytokines, among them IL-4, IL-13, and IL-31[2]. Picture a smoke alarm that keeps shrieking long after the burnt toast has gone in the bin. If you want the biology behind that, read the root causes of atopic dermatitis.

Atopic eczema treatment ladder by severity showing moisturizer foundation, OTC and prescription topicals, and systemic drugs for eczema
Treatment Mild Moderate Severe Role in the plan
OTC moisturizers (emollients) Yes Yes Yes Foundation at every step, twice daily[3]
OTC prebiotic moisturizers Yes Yes Yes Adjunct that supports skin flora alongside emollients
Perfect Repair (OTC prebiotic moisturizer) Yes Yes Yes Companion moisturizer to SmartLotion; natural ceramide barrier repair applied at least twice daily, all ages, rash or not
OTC 1% hydrocortisone Yes No No Short-term relief for mild patches only
SmartLotion (OTC) Yes Yes Yes All-in-one anti-inflammatory, prebiotic, and moisturizing step for daily long-term use; adjunct rather than a substitute for prescription therapy in severe disease
Prescription topicals Yes Yes Yes Steroids, calcineurin inhibitors, PDE4 and JAK creams for flares and maintenance
Phototherapy (NB-UVB) No Yes Yes Office-based option when topicals fall short[16]
Biologics and oral JAK inhibitors No Yes Yes Systemic control for disease not managed by optimized topicals[12]

The practical takeaway: severity decides how strong your anti-inflammatory needs to be, not whether you moisturize[4].

Every step on that ladder rests on a topical, so the tube you choose shapes everything above it. Which one you pick is where most treatment plans go wrong.

Topical Eczema Treatments: Steroids, Calcineurin Inhibitors, and PDE4/JAK Creams

Standing in front of a shelf of tubes that all promise relief is where most people give up and grab whatever is cheapest. Five options cover almost all topical eczema treatments, and four of them are prescription drug classes that each block inflammation at a different point in the chain, rather like shutting off a leak at different valves along the same pipe. The fifth is a complete over-the-counter option. Topical steroids, calcineurin inhibitors, crisaborole, and ruxolitinib cream each have an established place in that list, while topical antihistamines are not considered an effective anti-inflammatory option for atopic eczema. Whichever you use, you layer it on top of twice-daily moisturizing.

Topical corticosteroids: the first-line anti-inflammatory

Topical steroids remain the first-line choice for an active flare, and they work fast. They switch off a broad set of inflammatory signals in the skin. Potency has to match the site, because skin thickness controls how much drug gets absorbed. Thin eyelid and fold skin absorbs far more of the same product than thick palm skin does[5]. Eyelid skin behaves like tissue paper while the palm behaves like leather, so an identical dab of cream delivers very different doses.

Side effects track with three things: potency, how long you use it, and where you put it. Long high-potency use on thin skin can thin that skin further, although a systematic review found that intermittent use of mild-to-moderate potency steroids for flares produced little to no measurable skin thinning[5]. For the potency ladder, prescription names, and what to do about topical steroid withdrawal, see that dedicated guide.

Tacrolimus ointment for atopic dermatitis and pimecrolimus: steroid-free calcineurin inhibitors

Calcineurin inhibitors block calcineurin, an enzyme inside T cells (the immune cells that give the orders during a flare), so those cells never send the signal to attack[23]. It works rather like pulling the batteries out of a walkie-talkie. Tacrolimus ointment for atopic dermatitis comes in 0.03% for children age 2 and older and 0.1% for older teens and adults[6]. Pimecrolimus 1% cream is the milder sibling and is used in young children.

Two features make them valuable. First, they do not thin skin, so they suit the face, eyelids, neck, and skin folds where steroids carry more risk. Second, when researchers pool many trials and compare the results indirectly, tacrolimus 0.1% lands on roughly the same footing as a mid-potency steroid for many patients, though few studies have tested the two head to head[6]. The trade-off is early stinging or warmth at the application site, which usually settles within the first week[7]. US labeling still carries a boxed warning, the strongest caution the FDA can require, about a theoretical cancer risk that long-term studies have not confirmed, so ask your dermatologist about your personal risk factors before committing to long-term use. If burning has made you quit before, ask your dermatologist about ways to reduce it, such as a brief course of a mild steroid to settle skin before switching to the calcineurin inhibitor.

PDE4 and JAK creams: the newest non-steroid options

Three newer classes have joined the shelf, and none of them is a steroid. PDE4 inhibitors block an enzyme that destroys cAMP, a molecule that acts as the skin cell's own brake pedal on inflammation. Keep that brake pressed down and the flow of inflammatory cytokines falls[8].

Two PDE4 creams are on pharmacy shelves now. Crisaborole 2% ointment is approved from 3 months of age, and in a long-term study about half of users reached clear or almost clear skin during the first eight weeks, when everyone knew they were receiving the drug[8]. Roflumilast cream 0.15% is cleared for age 6 and older. About one in three patients had clear or almost clear skin by week 4, compared with roughly one in eight using the same cream base without the active ingredient[10].

Ruxolitinib 1.5% cream works differently. It blocks JAK1 and JAK2 signaling, the relay station for itch and inflammation messages, and it cut itch scores within days in the large final-stage trials that supported its approval for patients age 12 and older[9]. Tapinarof 1% cream is the fourth new class. It switches on the aryl hydrocarbon receptor, a control switch inside skin cells that turns inflammation down and helps rebuild the barrier, and it is approved from age 2 after showing significant improvements in disease severity and quality of life versus vehicle in its phase 3 ADORING trials[11]. All four share one real drawback: cost and insurance approval often decide whether you get them.

Comparison chart of topical eczema treatments including corticosteroids, calcineurin inhibitors, PDE4 creams, JAK creams, and SmartLotion
Class Examples What it blocks Best body sites Ages Speed Main drawback
Topical corticosteroids Hydrocortisone, triamcinolone, clobetasol Broad inflammatory gene activity Trunk and limbs; low potency only on face and folds Most ages, potency matched to age Days Thinning with long high-potency use[5]
Calcineurin inhibitors Tacrolimus 0.03% and 0.1%, pimecrolimus 1% Calcineurin inside T cells Face, eyelids, neck, folds Tacrolimus from age 2; pimecrolimus in young children 1 to 3 weeks[6] Burning in the first week[7]
PDE4 inhibitors Crisaborole 2%, roflumilast 0.15% PDE4 enzyme, raising cAMP Face and body Crisaborole from 3 months; roflumilast from age 6 2 to 4 weeks[8] Application stinging and cost[8]
JAK and AhR creams Ruxolitinib 1.5%, tapinarof 1% JAK1 and JAK2 signaling; AhR pathway Face and body, limited surface area Ruxolitinib from age 12; tapinarof from age 2 Itch relief within days[9] Surface-area limits and access
SmartLotion (OTC) 0.75% hydrocortisone with sulfur Inflammation, while supporting skin flora All sites, including face, eyelids, and folds All ages Days Mild stinging on first uses

Clinical Pearl: why thin skin changes the whole plan

  • Absorption is not uniform: the same product delivers far more drug through eyelid and fold skin than through forearm skin[5].
  • Site drives class choice: in clinical practice, face and fold eczema does better on a low-potency or non-steroid option used steadily than on a strong steroid used in bursts.

How to choose a topical eczema treatment

Five questions narrow the field fast. Work through them in order.

  1. Where is it? Face, eyelids, neck, and folds favor non-steroid classes or the mildest steroid options[5].
  2. How old is the patient? Age gates several products, so approval range often decides the class before anything else.
  3. Flare or maintenance? Fast anti-inflammatories control flares; gentler options carry the long stretches between them.
  4. How fast do you need relief? Steroids and JAK creams move quickest on itch, while PDE4 creams build over weeks[9].
  5. What has already failed? If a class failed at correct strength and duration, change the mechanism instead of the brand.
Decision flow diagram for choosing a topical medicine for eczema by body site, age, and severity

Site-specific plans help most when eczema keeps returning to one place. We cover atopic dermatitis on the face separately, and mild atopic dermatitis hands treatment follows different rules again because palm skin is thick and washes constantly.

📚 Related Resource

See our guide: What Cream Is Good for Eczema?

SmartLotion: the all-in-one OTC eczema cream option

Most topical medications for eczema handle one job. SmartLotion was built to handle three at once, which is why it sits on its own row in both tables above. It combines 0.75% hydrocortisone to calm inflammation, sulfur intended to support the skin microbiome (the community of bacteria that lives on healthy skin), and a moisturizing base with glycerin and grapefruit seed extract. It is formulated as an eczema cream for daily long-term use rather than a two-week rescue. This specific combination was not among the products reviewed in the published pooled analysis of topical eczema treatments.[27]

Because of that formulation, it works on the face, eyelids, and folds, at any age, and across all severity levels. It also layers safely alongside a prescription topical. Dr. Steven Harlan developed it during more than 30 years of dermatology practice, and you can read how it came out of that clinical work plus why the hydrocortisone in SmartLotion does not cause the usual side effects. Two honest notes: some people feel mild stinging for the first few applications, and uncommon severe cases start with a short prescription steroid course before tapering to SmartLotion for maintenance. Our adult atopic dermatitis protocol walks through both paths.

For most people, the right topical plus consistent moisturizing is enough. When it is not, the next step works from the inside, calming the immune signals before they ever reach your skin, which is worth understanding even if you never need it.

Atopic Dermatitis Medication Beyond Creams: Systemic Drugs for Eczema

Some people do everything right, greasing up twice a day and using the prescription cream exactly as directed, and still wake to scratched sheets. That is when systemic treatment, meaning medicine that works through the whole body rather than on one patch of skin, enters the picture[12]. These drugs target the same type 2 immune pathway as the creams do, just further upstream, closer to the tap than to the puddle on the floor[2]. If you are unsure where your skin falls on the scale, see how severe eczema is graded.

Cross-section illustration showing where atopic dermatitis medication blocks inflammation in the skin barrier and immune pathway

Biologics for atopic dermatitis

Biologics are lab-made antibodies you inject, and each one mops up a single inflammatory signal the way a key fits only one lock. Dupilumab blocks IL-4 and IL-13 receptor signaling and reached EASI-75, meaning a 75% drop in the standard eczema severity score, in roughly half of adults in its phase 3 trials, with itch scores falling in the first weeks[13]. Tralokinumab and lebrikizumab target IL-13 alone, and nemolizumab targets IL-31, the itch cytokine[14].

Injections run every two to four weeks depending on the drug, and you give them at home[24]. They do not require lab monitoring, which is a genuine advantage for busy families[12]. Response builds over weeks to months rather than days, with marked improvement often by week 4 and fuller clearance by around month 4[25].

Oral JAK inhibitors and older systemic drugs for eczema

Oral JAK inhibitors act faster. Upadacitinib and abrocitinib reduced itch within the first week or two of treatment, and reviewers describe that speed as a potential advantage over dupilumab[15]. That speed comes with boxed warnings and required blood monitoring, so your dermatologist screens you first and checks labs on a schedule[15].

Older options still earn their place. Narrowband UVB is phototherapy, a measured dose of ultraviolet light given in a clinic booth, and it improves moderate disease over two to three months of visits[16]. Cyclosporine and methotrexate are older pills that quiet the whole immune system rather than one signal: cyclosporine works quickly for short bursts, while methotrexate suits slower long-term control[26]. Oral and injected corticosteroids are the exception: guidelines advise against routine use because eczema commonly rebounds harder when they stop[12]. Two add-ons round things out. Wet wrap therapy, which means sealing damp dressings over your cream so more of it soaks in, is sometimes used during a severe flare, and antibiotics for infected eczema belong only in a true clinical infection, not in routine colonization, which simply means bacteria living quietly on the skin as they do on nearly everyone with eczema[20].

Option Examples How it is given What it targets Who it is for
Biologics Dupilumab, tralokinumab, lebrikizumab, nemolizumab Injection every 2 to 4 weeks[24] IL-4, IL-13, or IL-31 signals[14] Moderate to severe disease; no lab monitoring needed[13]
Oral JAK inhibitors Upadacitinib, abrocitinib Daily pill JAK enzymes across several cytokines Severe or fast-relief cases; requires monitoring[15]
Phototherapy Narrowband UVB Office visits, about 3 to 5 times weekly Skin immune activity Moderate disease, drug-free preference[16]
Older immunosuppressants Cyclosporine, methotrexate Pill or liquid Broad immune suppression Bridge or cost-limited options[12]

⚠️ Systemic drugs are an addition, not a replacement:

You keep moisturizing twice daily and keep treating breakthrough patches with a topical while on any systemic medicine[3].

Clearing a flare is only half the job. Atopic eczema comes back unless the plan changes once your skin looks normal.

How to Get Rid of Atopic Dermatitis Flares and Keep Them From Returning

Here is where most people slip. The rash clears, the creams go back in the cupboard, and six weeks later the same patch flares again. Skin that looks normal is not the same as healed skin. Invisible inflammation lingers in the old spots like embers under a campfire that appears to be out, which is why the answer to how to get rid of atopic dermatitis is a maintenance plan rather than a cure[19].

Proactive maintenance therapy: the twice-a-week rule

Proactive therapy means treating the places that used to flare, even when they look fine. After the skin clears, you apply a topical steroid or calcineurin inhibitor to those old hot spots about twice a week. Long-term studies of proactive pimecrolimus and tacrolimus show this delays flares and prevents relapses compared with treating only when the rash returns[17].

Moisturizer stays daily underneath all of it, and that alone reduces how often flares happen[3]. SmartLotion fits this stage well because its formulation is designed for continuous daily use, so many people keep it as their eczema treatment cream between flares. Cutting exposure matters too, so it helps to know your personal eczema triggers before the next season change.

Timeline showing atopic eczema treatment from flare control in weeks one and two to twice-weekly proactive maintenance therapy

Week 1-2

Daily anti-inflammatory on active patches plus moisturizer twice a day

Week 3-4

Skin calms, so you taper the anti-inflammatory instead of stopping cold

Month 2+

Twice-weekly proactive treatment of old hot spots, moisturizer still daily[17]

Ongoing

Written flare plan ready, so day one of a flare never becomes week three

Your written flare plan

If you do only one thing: moisturize twice a day, every day, flare or not. Eczema-prone skin is short on filaggrin, the protein the barrier needs to hold water, so it cannot stay hydrated on its own. Perfect Repair prebiotic moisturizer is the twice-daily moisturizer Dr. Harlan designed for that job, while SmartLotion treats the inflamed skin.

  • Day 1 of a flare: start your anti-inflammatory on the affected area twice daily, and do not wait for it to spread.
  • Days 2 to 7: keep going even as redness fades, since the inflammation clears after the color does[17].
  • Week 2: if the patch has not improved, change class rather than adding more of the same product.
  • After clearing: drop to twice-weekly proactive use on that same spot.

Write those four lines on paper and keep them where the creams live. A plan you can read at 2 a.m. beats a plan you half remember.

📚 Related Resource

See our guide: How Do You Get Rid of Eczema? A 4-Step Clearing Plan

Most atopic eczema can be controlled at home with this plan, but a few signs mean home care has run out of road, and waiting only makes the next flare harder to reverse.

When to See a Dermatologist About Atopic Eczema Treatment

By the third sleepless week, or the first time a patch starts weeping, home care is no longer the right tool. Book an appointment when self-management stops working or when the picture changes, because these situations need professional eyes.

  • No improvement in 2 to 4 weeks: correct use of a topical should show progress by then.
  • Signs of infection: weeping, honey-colored crusts, or fever suggest bacterial infection, and because eczema-prone skin so often carries Staphylococcus aureus (a common skin bacterium) without any harm, antibiotics are reserved for true clinical infection[20].
  • Broken sleep most nights: sleep disruption affects a large share of people with active atopic dermatitis and signals undertreatment[21].
  • Wide or repeated facial involvement: large areas and eyelid flares call for a site-matched prescription plan.
  • You are considering systemic therapy: eligibility and monitoring both need a specialist[12].

⚠️ Seek urgent care for these signs:

Painful clusters of punched-out sores, rapid spreading, or fever can mean eczema herpeticum, a cold sore virus spreading across eczema-damaged skin, which needs antiviral treatment right away[22].

Frequently Asked Questions About Treating Atopic Eczema

What is the best medicine for eczema?

No single medicine wins for everyone, because severity and body site change the answer. Topical steroids remain the fastest first-line choice for flares. For a complete option you can use daily and long term, SmartLotion combines an anti-inflammatory, prebiotic microbiome support, and moisture in one OTC eczema cream.

Is tacrolimus ointment better than steroid cream for atopic dermatitis?

Neither is universally better. In indirect comparisons, tacrolimus performs broadly comparably to a mid-potency steroid for many patients and does not thin skin, which makes it a strong pick for the face, eyelids, and folds[6]. Steroids act faster, while tacrolimus often burns slightly during the first week[7].

What is the 3 minute rule for eczema?

The 3 minute rule means applying your moisturizer or medicine within about three minutes of getting out of the bath or shower. This timing is mainly a convenient habit cue rather than a proven hydration boost, since studies comparing immediate and delayed application after bathing have found no significant difference in skin hydration[18]. Consistent emollient use on this schedule reduces flare frequency[3].

What should you not put on atopic eczema?

Skip topical antihistamines, since they are not an established anti-inflammatory treatment for atopic dermatitis. Avoid rubbing alcohol, undiluted essential oils, and harsh synthetic fragrance blends that sting broken skin. Gentle hypoallergenic scents are a different matter. Also keep high-potency steroids off the face and folds unless a dermatologist directs it[5].

Can atopic dermatitis be cured permanently?

No treatment cures atopic dermatitis, and many cases continue into adult life even after childhood improvement[19]. Long stretches of clear, comfortable skin are realistic with maintenance. Many people hold that control with daily moisturizing, proactive twice-weekly therapy[17], and a formulation such as SmartLotion that suits long-term daily use.

Is atopic dermatitis treatment different from other eczema treatment?

The anti-inflammatory tools overlap, but the strategy differs. Atopic treatment adds long-term barrier repair and proactive maintenance because the immune driver never fully leaves[2]. By contrast, contact dermatitis treatment centers on identifying and removing the substance causing the reaction.

References

  1. Bylund S, von Kobyletzki LB, Svalstedt M, Svensson Å. "Prevalence and Incidence of Atopic Dermatitis: A Systematic Review." Acta Dermato-Venereologica. 2020. View Study
  2. D'Avino P, Kim J, Li M, et al. "Distinct Roles of IL-4, IL-13, and IL-22 in Human Skin Barrier Dysfunction and Atopic Dermatitis." Allergy. 2025;81(2):480–497. View Study
  3. van Zuuren EJ, Fedorowicz Z, Christensen R, Lavrijsen APM, Arents BWM. "Emollients and moisturisers for eczema." Cochrane Database of Systematic Reviews. 2017. View Study
  4. Molla A. "Phototherapy in Atopic Dermatitis Management." Atopic Dermatitis - Bridging the Gap between Clinical Science and Practical Care. 2025. View Study
  5. Harvey J, Lax SJ, Lowe A, et al. "The long-term safety of topical corticosteroids in atopic dermatitis: A systematic review." Skin Health and Disease. 2024. View Study
  6. Murota H, Nakahara T, Wang X, et al. "Systematic Literature Review and Network Meta-Analysis of Clinical Efficacy and Safety of Topical Treatments for Patients with Atopic Dermatitis." Dermatology and Therapy. 2025. View Study
  7. Draelos ZD, Feldman SR, Berman B, et al. "Tolerability of Topical Treatments for Atopic Dermatitis." Dermatology and Therapy. 2019. View Study
  8. Eichenfield LF, Gower RG, Xu JH, et al. "Once-Daily Crisaborole Ointment, 2%, as a Long-Term Maintenance Treatment in Patients Aged ≥ 3 Months with Mild-to-Moderate Atopic Dermatitis: A 52-Week Clinical Study." American Journal of Clinical Dermatology. 2023. View Study
  9. Eichenfield LF, Simpson EL, Papp K, et al. "Efficacy, Safety, and Long-Term Disease Control of Ruxolitinib Cream Among Adolescents with Atopic Dermatitis: Pooled Results from Two Randomized Phase 3 Studies." American Journal of Clinical Dermatology. 2024. View Study
  10. Simpson EL, Eichenfield LF, Alonso-Llamazares J, et al. "Roflumilast Cream, 0.15%, for Atopic Dermatitis in Adults and Children: INTEGUMENT-1 and INTEGUMENT-2 Randomized Clinical Trials." JAMA Dermatology. 2024;160(11):1161–1170. View Study
  11. Simpson EL, Hebert AA, Browning J, et al. "Tapinarof Improved Outcomes and Sleep for Patients and Families in Two Phase 3 Atopic Dermatitis Trials in Adults and Children." Dermatology and Therapy. 2025. View Study
  12. Eichenfield LF, Boguniewicz M, Lauren CT, et al. "Systemic Therapy for Atopic Dermatitis in Children and Adolescents: A US Expert Consensus." Dermatology. 2024;240(5-6):897–909. View Study
  13. Griffiths C, de Bruin-Weller M, Deleuran M, et al. "Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four Phase 3 Trials." Dermatology and Therapy. 2021. View Study
  14. Shergill M, Bajwa B, Yilmaz O, Tailor K, Bouadi N, Mukovozov I. "Biologic and Small Molecule Therapy in Atopic Dermatitis." Biomedicines. 2024. View Study
  15. Nezamololama N, Fieldhouse K, Metzger K, Gooderham M. "Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib." Drugs in Context. 2020. View Study
  16. Patrizi A, Raone B, Ravaioli GM. "Management of atopic dermatitis: safety and efficacy of phototherapy." Clinical, Cosmetic and Investigational Dermatology. 2015. View Study
  17. Luk D, Hon KLE, Dizon MVC, et al. "Practical Recommendations for the Topical Treatment of Atopic Dermatitis in South and East Asia." Dermatology and Therapy. 2021. View Study
  18. Chiang C, Eichenfield LF. "Quantitative assessment of combination bathing and moisturizing regimens on skin hydration in atopic dermatitis." Pediatric Dermatology. 2009. View Study
  19. Abuabara K, Ye M, Margolis DJ, et al. "Patterns of Atopic Eczema Disease Activity From Birth Through Midlife in 2 British Birth Cohorts." JAMA Dermatology. 2021. View Study
  20. Wang V, Boguniewicz J, Boguniewicz M, Ong PY. "The infectious complications of atopic dermatitis." Annals of Allergy, Asthma & Immunology. 2021;126(1):3-12. View Study
  21. Bawany F, Northcott CA, Beck LA, Pigeon WR. "Sleep Disturbances and Atopic Dermatitis: Relationships, Methods for Assessment, and Therapies." Journal of Allergy and Clinical Immunology: In Practice. 2021. View Study
  22. Traidl S, Heratizadeh A, Werfel T. "Algorithms in Allergy: Diagnosis and Treatment of Atopic Dermatitis Complicated by Eczema Herpeticum." Allergy. 2025. View Study
  23. Ulengin-Talkish I, Cyert MS. "A cellular atlas of calcineurin signaling." Biochimica et Biophysica Acta - Molecular Cell Research. 2022. View Study
  24. Lim XQ, Winter E, Nograles K, et al. "A First-in-Human, Single- and Multiple-Dose Study of APG777, a Half-Life-Extended Anti-IL-13 Monoclonal Antibody, in Healthy Volunteers." Clinical and Translational Science. 2025. View Study
  25. Wang M, Gao XH, Zhang L. "A Review of Dupilumab in the Treatment of Atopic Dermatitis in Infants and Children." Drug Design, Development and Therapy. 2024. View Study
  26. Flohr C, et al. "Efficacy and safety of ciclosporin versus methotrexate in the treatment of severe atopic dermatitis in children and young people (TREAT): a multicentre parallel group assessor-blinded clinical trial." British Journal of Dermatology. 2023. View Study
  27. Lax SJ, et al. "Topical anti-inflammatory treatments for eczema: network meta-analysis." The Cochrane Database of Systematic Reviews. 2024. View Study

About the Author: Lisa Jensen, Senior Clinical Research Associate

Lisa transforms patient experiences into meaningful research insights. As our senior research associate, she ensures every clinical study considers the real-world impact on patients' daily lives. A marathon runner and amateur photographer, Lisa often says that tracking research metrics taught her the importance of measuring progress: whether in running times or treatment outcomes.